CoChat

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

Open access
Storb, Rainer, Gyurkocza, Boglarka, Storer, Barry E., Sorror, Mohamed L., Blume, Karl, Niederwieser, Dietger, Chauncey, Thomas R., Pulsipher, Michael A., Petersen, Finn B., Sahebi, Firoozeh, Agura, Edward D., Hari, Parameswaran, Bruno, Benedetto, McSweeney, Peter A., Maris, Michael B., Maziarz, Richard T., Langston, Amelia A., Bethge, Wolfgang, Vindeløv, Lars, Franke, Georg-Nikolaus, Laport, Ginna G., Yeager, Andrew M., Hübel, Kai, Deeg, H. Joachim, Georges, George E., Flowers, Mary E.D., Martin, Paul J., Mielcarek, Marco, Woolfrey, Ann E., Maloney, David G., Sandmaier, Brenda M. · 2013 · Journal of Clinical Oncology
Cited by 214

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Purpose: We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies unable to tolerate high-intensity regimens because of age, serious comorbidities, or previous high-dose HCT. The regimen allows the purest assessment of graft-versus-tumor (GVT) effects apart from conditioning and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities. Patients and Methods: Patients received low-dose total-body irradiation ± fludarabine before HCT from HLA-matched related (n = 611) or unrelated (n = 481) donors, followed by mycophenolate mofetil and a calcineurin inhibitor to aid engraftment and control GVHD. Median patient age was 56 years (range, 7 to 75 years). Forty-five percent of patients had comorbidity scores of ≥ 3. Median follow-up time was 5 years (range, 0.6 to 12.7 years). Results: Depending on disease risk, comorbidities, and GVHD, lasting remissions were seen in 45% to 75% of patients, and 5-year survival ranged from 25% to 60%. At 5 years, the nonrelapse mortality (NRM) rate was 24%, and the relapse mortality rate was 34.5%. Most NRM was a result of GVHD. The most significant factors associated with GVHD-associated NRM were serious comorbidities and grafts from unrelated donors. Most relapses occurred early while the immune system was compromised. GVT effects were comparable after unrelated and related grafts. Chronic GVHD, but not acute GVHD, further increased GVT effects. The potential benefit associated with chronic GVHD was outweighed by increased NRM. Conclusion: Allogeneic HCT relying on GVT effects is feasible and results in cures of an appreciable number of malignancies. Improved results could come from methods that control progression of malignancy early after HCT and effectively prevent GVHD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.45.0247

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 214

Metadata

Authors
Storb, R., Gyurkocza, B., Storer, B. E., Sorror, M. L., Blume, K., Niederwieser, D., Chauncey, T. R., Pulsipher, M. A., Petersen, F. B., Sahebi, F., Agura, E. D., Hari, P., Bruno, B., McSweeney, P. A., Maris, M. B., Maziarz, R. T., Langston, A. A., Bethge, W., Vindeløv, L., Franke, G.-N., Laport, G. G., Yeager, A. M., Hübel, K., Deeg, H. J., Georges, G. E., Flowers, M. E. D., Martin, P. J., Mielcarek, M., Woolfrey, A. E., Maloney, D. G., & Sandmaier, B. M.
Venue
Journal of Clinical Oncology
Published
2013-04-20
Volume
31
Issue
12
Pages
1530-1538
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2111717354
Cited by
214
References
2
FWCI
16.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. https://app.cochat.ai/papers/10.1200/jco.2012.45.0247
The paper
Storb, R., Gyurkocza, B., Storer, B. E., Sorror, M. L., Blume, K., Niederwieser, D., Chauncey, T. R., Pulsipher, M. A., Petersen, F. B., Sahebi, F., Agura, E. D., Hari, P., Bruno, B., McSweeney, P. A., Maris, M. B., Maziarz, R. T., Langston, A. A., Bethge, W., Vindeløv, L., . . . Sandmaier, B. M. (2013). Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.45.0247

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.